Nuvalent, Inc.
NUVL
Helyezés a részvények között
#2106
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Részvényárfolyam
$123.96
Utolsó szinkronizálás: 2026-07-21
Piaci kapitalizáció
$9.75B
Változás (1 nap)
0.00%
Változás (1 év)
26.53%
Ország
US
Kereskedés Nuvalent, Inc. (NUVL)
Kategória
Healthcare
EPS Nuvalent, Inc. (NUVL) részvényre
EPS March 2026 dátummal, TTM: $-6.06
Nuvalent, Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi EPS mutatója (TTM) $-6.06. 2023 végén a vállalat EPS mutatója $-2.17 volt, növekedés a 2022 év EPS értékéhez, amely $-1.65 volt.
Nuvalent, Inc. EPS története 2019 és 2026 között
EPS minden év végén
| Év | EPS | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $-6.06 | 54.20% |
| 2024 | $-3.93 | 81.11% |
| 2023 | $-2.17 | 31.52% |
| 2022 | $-1.65 | -22.54% |
| 2021 | $-2.13 | 232.81% |
| 2020 | $-0.64 | 166.67% |
| 2019 | $-0.24 | 0.00% |
EPS hasonló cégek vagy versenytársak esetén
| Vállalat | EPS | EPS különbség | Ország |
|---|---|---|---|
| $17.32 | -385.81% |
US
|
|
| $-7.98 | 31.68% |
US
|
|
| $-5.29 | -12.71% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -557.76% |
NL
|
